Medi Caps (BSE 523144)₹25.42+5.00%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Medi Caps reported sales of ₹2.80 Cr, up 3.7% from Jun 2025, and net profit of −₹2.22 Cr. For the year to Mar 2026, sales were ₹12.49 Cr and net profit −₹3.03 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.05 | 7.10 | 7.90 | 6.23 | 8.32 | 4.03 | 6.99 | 2.70 | 2.03 | 4.31 | 3.46 | 2.80 |
| Expenses | 5.54 | 6.38 | 8.38 | 6.49 | 7.83 | 5.81 | 7.21 | 6.08 | 4.94 | 5.35 | 5.52 | 4.63 |
| Operating Profit | 0.49 | 0.69 | −0.49 | −0.27 | 0.44 | −1.77 | −0.24 | −3.37 | −2.90 | −1.05 | −2.05 | −1.82 |
| OPM % | 8.3% | 9.9% | −6.4% | −4.5% | 5.4% | −44.3% | −3.3% | −125.7% | −144.1% | −24.7% | −59.7% | −65.6% |
| Other Income | 0.08 | 0.10 | 0.25 | 0.16 | 0.30 | 0.17 | 2.15 | 0.34 | 1.54 | 0.77 | 5.60 | 0.06 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.46 | 0.46 | 0.34 | 0.44 | 0.44 | 0.44 | 0.45 | 0.45 | 0.45 | 0.45 | 0.51 | 0.46 |
| Profit before tax | 0.11 | 0.33 | −0.58 | −0.55 | 0.30 | −2.04 | 1.44 | −3.49 | −1.81 | −0.73 | 3.02 | −2.22 |
| Tax % | 0.0% | 150.1% | 83.1% | 0.0% | 0.0% | 0.0% | −18.6% | 0.0% | 0.0% | 4.1% | −0.3% | 0.0% |
| Net Profit | 0.11 | −0.15 | −1.09 | −0.57 | 0.32 | −2.04 | 1.71 | −3.48 | −1.81 | −0.76 | 3.03 | −2.22 |
| EPS (Rs) | 0.11 | −0.14 | −0.88 | −0.46 | 0.26 | −1.65 | 1.39 | −2.81 | −1.47 | −0.63 | 2.45 | −1.80 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.13 | 44.21 | 53.91 | 51.96 | 43.19 | 57.63 | 70.14 | 49.51 | 27.47 | 25.56 | 12.49 | 12.60 |
| Expenses | 40.41 | 42.44 | 51.52 | 47.06 | 49.82 | 46.44 | 59.86 | 44.21 | 27.37 | 27.29 | 21.88 | 20.44 |
| Operating Profit | 2.60 | 1.60 | 2.16 | 4.71 | −6.74 | 10.95 | 10.06 | 5.20 | 0.00 | −1.81 | −9.41 | −7.82 |
| OPM % | 6.1% | 3.7% | 4.1% | 9.1% | −15.7% | 19.1% | 14.4% | 10.5% | 0.0% | −7.1% | −75.7% | −62.1% |
| Other Income | 0.69 | 2.03 | 1.08 | 2.74 | 2.87 | 1.78 | 1.96 | 1.50 | 0.49 | 2.74 | 8.22 | 7.97 |
| Interest | 0.07 | 0.11 | 0.11 | 0.14 | 0.13 | 0.11 | 0.12 | 0.14 | 0.05 | 0.06 | 0.02 | 0.00 |
| Depreciation | 1.81 | 1.82 | 1.80 | 1.83 | 1.84 | 1.53 | 1.82 | 1.75 | 1.70 | 1.73 | 1.82 | 1.87 |
| Profit before tax | 1.42 | 1.71 | 1.34 | 5.49 | −5.83 | 11.11 | 10.08 | 4.80 | −1.24 | −0.83 | −3.02 | −1.74 |
| Tax % | 39.2% | 20.4% | 14.9% | 2.2% | 0.2% | −0.1% | 0.1% | 63.7% | 80.1% | −32.1% | 0.7% | — |
| Exceptional items | 0.00 | 0.43 | 0.03 | 0.25 | 0.41 | −0.11 | 0.46 | 0.52 | 0.18 | 1.77 | 0.00 | — |
| Net Profit | 0.85 | 1.36 | 1.14 | 5.38 | −5.86 | 11.12 | 10.07 | 1.77 | −2.25 | −0.56 | −3.03 | −1.76 |
| EPS (Rs) | 0.70 | 1.11 | 0.93 | 4.33 | −4.70 | 8.94 | 8.09 | 1.42 | −1.81 | −0.47 | −2.45 | −1.45 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.50 | 12.48 | 12.50 | 12.49 | 12.49 | 12.49 | 12.49 | 12.49 | 12.49 | 12.49 | 12.48 | 12.49 |
| Reserves | 68.93 | 69.70 | 76.62 | 77.67 | 83.06 | 78.43 | 92.14 | 104 | 106 | 108 | 109 | 99.05 |
| Borrowings | 0.82 | 0.09 | 0.10 | 0.18 | 0.13 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 7.03 | 10.74 | 8.23 | 10.57 | 10.95 | 4.22 | 10.16 | 14.16 | 7.46 | 6.34 | 4.16 | 3.87 |
| Total Liabilities | 89.28 | 93.01 | 97.45 | 101 | 107 | 95.21 | 115 | 130 | 126 | 127 | 125 | 115 |
| Fixed Assets | 58.15 | 56.46 | 62.27 | 61.09 | 59.92 | 57.39 | 58.23 | 59.41 | 58.97 | 58.71 | 57.25 | 55.29 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.96 | 0.53 | 0.23 | 0.00 | 0.00 | 0.07 | 0.00 |
| Investments | 5.41 | 6.71 | 7.81 | 11.15 | 16.29 | 21.90 | 29.32 | 30.54 | 31.97 | 38.27 | 42.86 | 35.80 |
| Other Assets | 25.72 | 29.84 | 27.37 | 28.67 | 30.42 | 14.96 | 26.71 | 40.07 | 34.98 | 30.20 | 25.08 | 24.32 |
| Inventories | 13.45 | 14.98 | 13.21 | 10.17 | 10.95 | 5.46 | 6.72 | 11.86 | 7.06 | 5.75 | 3.19 | 2.93 |
| Trade receivables | 8.63 | 9.70 | 8.95 | 13.04 | 12.86 | 4.40 | 6.38 | 10.08 | 8.45 | 10.81 | 8.80 | 6.91 |
| Cash & equivalents | 0.89 | 1.29 | 2.12 | 2.31 | 2.47 | 1.24 | 6.80 | 9.74 | 1.10 | 0.31 | 0.40 | 0.49 |
| Total Assets | 89.28 | 93.01 | 97.45 | 101 | 107 | 95.21 | 115 | 130 | 126 | 127 | 125 | 115 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 7.06 | 2.60 | 4.03 | 4.21 | 5.97 | 4.64 | 15.33 | 7.03 | −6.09 | 6.95 | 5.08 | −7.03 |
| Cash from investing activity | −6.99 | −1.48 | 2.58 | −4.10 | −5.76 | −5.81 | −9.72 | −4.09 | −2.57 | −7.75 | −4.99 | 7.13 |
| Cash from financing activity | 0.00 | −0.74 | −5.77 | 0.09 | −0.06 | −0.07 | −0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net cash flow | 0.07 | 0.38 | 0.82 | 0.19 | 0.15 | −1.22 | 5.54 | 2.94 | −8.60 | −0.78 | 0.08 | 0.08 |
| Capex | 0.51 | 0.17 | 0.73 | 0.70 | 0.60 | 1.26 | 2.27 | 2.80 | 1.17 | 0.36 | 0.34 | 0.86 |
| Free cash flow | 6.56 | 2.42 | 9.08 | 3.50 | 5.36 | 3.37 | 13.02 | 4.22 | −7.22 | 6.57 | 4.73 | −7.85 |
| CFO / OP % | −9,750.0% | 120.0% | 270.0% | 202.0% | 128.0% | −69.0% | 140.0% | 70.0% | −58.0% | — | −267.0% | 74.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 88 | 83 | 75 | 90 | 92 | 38 | 42 | 54 | 64 | 145 | 127 | 204 |
| Inventory days | 265 | 256 | 229 | 147 | 163 | 74 | 82 | 156 | 121 | 242 | 120 | 189 |
| Days payable | 66 | 102 | 76 | 91 | 96 | 27 | 77 | 154 | 49 | 77 | 60 | 31 |
| Cash conversion cycle | 286 | 237 | 228 | 145 | 157 | 85 | 46 | 54 | 135 | 309 | 186 | 361 |
| Working capital days | 183 | 153 | 146 | 112 | 126 | 84 | 64 | 87 | 200 | 323 | 303 | 1,283 |
| ROCE % | −0.7% | 1.8% | 1.5% | 1.6% | 5.8% | −6.5% | 11.6% | 8.8% | 3.7% | −1.2% | −2.1% | −2.6% |
For the Jun 2026 quarter, Medi Caps reported sales of ₹2.80 Cr, up 3.7% year on year and net profit of −₹2.22 Cr. The operating margin was −65.6%.
Medi Caps' sales for the year to Mar 2026 were ₹12.49 Cr; over the last twelve months they were ₹12.60 Cr.
Net profit for the year to Mar 2026 was −₹3.03 Cr, and −₹1.76 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−1.45.
Medi Caps reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹0.49 Cr.
Cash from operations was −₹7.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹7.85 Cr.